These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31669239)

  • 1. Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations.
    Januškevičienė I; Petrikaitė V
    Life Sci; 2019 Dec; 239():117009. PubMed ID: 31669239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.
    Yang F; Cao L; Sun Z; Jin J; Fang H; Zhang W; Guan X
    Int J Biol Sci; 2016; 12(12):1568-1577. PubMed ID: 27994520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor Heterogeneity.
    Swarbrick A; Fernandez-Martinez A; Perou CM
    Cold Spring Harb Perspect Med; 2024 Jan; 14(1):. PubMed ID: 37137498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer.
    Dawood S; Gonzalez-Angulo AM
    Cancer Biomark; 2012-2013; 12(6):241-50. PubMed ID: 23735944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumoral heterogeneity of breast cancer.
    Roulot A; Héquet D; Guinebretière JM; Vincent-Salomon A; Lerebours F; Dubot C; Rouzier R
    Ann Biol Clin (Paris); 2016 Dec; 74(6):653-660. PubMed ID: 27848916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor intrinsic subtype is reflected in cancer-adjacent tissue.
    Casbas-Hernandez P; Sun X; Roman-Perez E; D'Arcy M; Sandhu R; Hishida A; McNaughton KK; Yang XR; Makowski L; Sherman ME; Figueroa JD; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2015 Feb; 24(2):406-14. PubMed ID: 25465802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.
    Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI
    OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
    Li S; Payne S; Wang F; Claus P; Su Z; Groth J; Geradts J; de Ridder G; Alvarez R; Marcom PK; Pizzo SV; Bachelder RE
    Breast Cancer Res; 2015 Jul; 17(1):91. PubMed ID: 26141457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumor Heterogeneity in Breast Cancer.
    Beca F; Polyak K
    Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
    Campoy EM; Branham MT; Mayorga LS; Roqué M
    BMC Cancer; 2019 Apr; 19(1):328. PubMed ID: 30953488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in chemical pharmacotherapy to manage advanced breast cancer.
    Gombos A; Awada A
    Expert Opin Pharmacother; 2017 Jan; 18(1):95-103. PubMed ID: 27927046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumor heterogeneity predicts metastasis of triple-negative breast cancer.
    Yang F; Wang Y; Li Q; Cao L; Sun Z; Jin J; Fang H; Zhu A; Li Y; Zhang W; Wang Y; Xie H; Gustafsson JÅ; Wang S; Guan X
    Carcinogenesis; 2017 Sep; 38(9):900-909. PubMed ID: 28911002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Heterogeneity in Breast Cancer.
    Turashvili G; Brogi E
    Front Med (Lausanne); 2017; 4():227. PubMed ID: 29276709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    Lindström LS; Yau C; Czene K; Thompson CK; Hoadley KA; Van't Veer LJ; Balassanian R; Bishop JW; Carpenter PM; Chen YY; Datnow B; Hasteh F; Krings G; Lin F; Zhang Y; Nordenskjöld B; Stål O; Benz CC; Fornander T; Borowsky AD; Esserman LJ;
    J Natl Cancer Inst; 2018 Jul; 110(7):726-733. PubMed ID: 29361175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity.
    Hong D; Fritz AJ; Zaidi SK; van Wijnen AJ; Nickerson JA; Imbalzano AN; Lian JB; Stein JL; Stein GS
    J Cell Physiol; 2018 Dec; 233(12):9136-9144. PubMed ID: 29968906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast tumor stroma: A driving force in the development of resistance to therapies.
    Majidinia M; Yousefi B
    Chem Biol Drug Des; 2017 Mar; 89(3):309-318. PubMed ID: 28042683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
    Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
    Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.